Key business with prescription medicines continues to boost growth at Boehringer Ingelheim

Boehringer IngelheimThe pharmaceutical company Boehringer Ingelheim again posted good business results for the first six months of 2007. The company grew by 2.1% in euro terms compared to EUR 5,296 million in 2006, achieving net sales of EUR 5,407 million. Currency-adjusted growth was 7.5%.

Key global products, such as Spiriva®, Micardis®, Mirapex®/Sifrol® performed strongly, driving growth. As foreseen, the overall growth rate was lower than in 2006, due mainly to competition from generics. This applied to Mobic® in the USA and Alna® in Europe.

Although the euro's strength against the US dollar and the Japanese yen also significantly contributed to slower growth, an operating income of EUR 1,001 million was achieved, compared to EUR 1,033 million in 2006. The operating return on sales fell only slightly compared to the first half of 2006 from 19.5% to 18.5%.

"Our growth is primarily driven by our innovative drugs which are readily accepted, due to their value for patients. This allowed us to achieve good business development and maintain our strategic growth path in the first half of the year, despite negative factors, such as Mobic® gone generic in the USA in July 2006 and unfavourable currency effects," said Dr Alessandro Banchi, Chairman of the Board of Managing Directors of Boehringer Ingelheim. "Importantly, we maintained growth in the USA, as well as in Europe and Asia, and again expect, currency-adjusted, double-digit growth and an operating margin of around 20% for the whole of 2007," he said.

Boehringer Ingelheim's core business, Prescription Medicines (PM), accounts for about 80% of the company's net sales. These drugs posted sales of EUR 4,310 million in the first six months, an increase of 2.6% in euro terms (+8.4% after currency adjustment) compared to 2006.

In the US, due to the generic competition for Mobic®, Prescription Medicines' sales were 3.7% lower, at EUR 1,932 million in euro terms. After currency adjustment, however, growth was 4.1%.

Asia, Australasia, Africa posted net sales of EUR 713 million, an improvement of 3.3% on 2006 in euro terms (currency-adjusted +12.3%). The weak yen meant that Japan only increased sales by 0.8% in euro terms to EUR 424 million. But after currency adjustment, Japan achieved gratifying growth of 12.6%.

In Europe, Boehringer Ingelheim posted net sales of EUR 1,182 million, with growth of 9.1% in euro terms (currency-adjusted +8.9%). Germany remained Boehringer Ingelheim's largest European market, with growth of 3.7% and net sales of EUR 234 million.

Respiratory products, accounted for 37% of Prescription Medicines' sales, forming the largest share. Spiriva®, for the treatment of chronic obstructive pulmonary disease (COPD), secured further strong growth of 32.5% in the first half of 2007 compared to 2006, with sales of EUR 847 million.

The leading cardiovascular product, Micardis®, a drug for the treatment of high blood pressure, posted a 17.8% increase in sales compared to the previous year to total EUR 563 million.

For urological disorders the company markets Flomax®/Alna®, a treatment for benign prostatic hyperplasia. This drug achieved growth of 16.6% over 2006, with net sales of EUR 522 million.

In the area of central nervous system disorders, Mirapex®/Sifrol®, for the treatment of Parkinson's disease and restless legs syndrome, achieved a gratifying performance, with sales rising to EUR 298 million (+14.3% compared to 2006).

Mobic®, in the area of inflammatory and immunological diseases, for the treatment of pain associated with arthritis, suffered a severe slump in sales after the market entry of generic competitors in the USA. Net sales totalled EUR 122 million compared to EUR 454 million in 2006.

Consumer Health Care (CHC), that accounts for 10.4% of the corporation's net sales, showed positive development, with growth of 7.4% in euro terms (currency-adjusted +12.5%) to EUR 560 million. The acquisition in the USA of Zantac® for the treatment and prevention of heartburn, not included in the 2006 sales figures, was the main growth driver here.

The Animal Health business made excellent progress in its core segments swine and small animals, achieving growth of 7.3% in euro terms (currency-adjusted +10.7%) on sales of EUR 195 million. In particular, the introduction of the vaccine Ingelvac® Circoflex™ for porcine circovirus 2 associated disease (PCVAD) in the USA and Canada boosted growth in the swine segment. The positive business development in the USA, with currency-adjusted growth of 11% compared to 2006, was particularly positive. Our other key products, Metacam®, Vetmedin® and Enterisol® Ilitis, also achieved double-digit growth in many regions compared to 2006.

Due to expected extraordinary effects, Biopharmaceuticals' sales were EUR 196 million, an 11.5% decline compared to 2006.

This year too, the company's growth was the basis for generating new jobs. Compared to the first half of 2006, Boehringer Ingelheim increased its employee capacity by 1,406 (+3.8%) to 38,351.

For further information, please visit:

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]